Viridian reports cash of $563.4M; BLA for veligrotug on track for 2H 2025

Viridian Therapeutics, Inc.\DE

Cash, cash equivalents and short-term investments $563.4M as of June 30, 2025, down from $636.6M at March 31, 2025; runway into 2H 2027.
R&D expenses $86.6M in Q2 2025 (up from $56.2M in Q2 2024) driven by more clinical trials and higher headcount.
Veligrotug BLA submission on track for 2H 2025; U.S. commercial launch anticipated in 2026 if approved.
Exclusive license with Kissei for Japan: $70M upfront, up to $315M in milestones, plus tiered royalties.
Veligrotug durability data: 70% of proptosis responders at week 15 maintained response at week 52.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.